68.00$
BPC-157, also known as Body Protection Compound-157, is a synthetic pentadecapeptide consisting of a 15‑amino‑acid chain. It is derived from a protective protein found in human gastric juice. This stable research compound is widely studied in preclinical laboratory settings, including in vitro cell cultures and animal models, primarily rodents, due to its potential cytoprotective, regenerative, and anti-inflammatory properties. BPC-157 is intended strictly for laboratory research use. It is not approved for human consumption, therapeutic use, or veterinary application. Regulatory agencies such as the FDA have not approved this compound for human use, and it remains in the preclinical research phase.
This BPC-157 compound contains 10 milligrams per vial, suitable for laboratory procedures requiring higher research quantities. It may be used in experimental models studying tissue repair processes over extended research periods.
In experimental research, BPC-157 demonstrates pleiotropic activity by influencing several important signaling pathways. Studies indicate activation of VEGFR2 and downstream Akt-eNOS pathways, supporting nitric oxide production and angiogenesis in both cellular and animal models. The peptide also increases FAK-paxillin signaling involved in cell migration and survival, upregulates growth hormone receptor expression, and interacts with JAK-2 signaling pathways. Additionally, BPC-157 may modulate inflammatory responses by reducing pro-inflammatory mediators such as Nos2 and Nfkb while supporting anti-inflammatory processes. These mechanisms are observed under controlled in vitro and in vivo laboratory conditions.
Preclinical animal studies involving induced injuries have explored the role of BPC-157 in tissue recovery. Research models demonstrate improved healing responses in musculoskeletal injuries including tendon transection, ligament damage, and muscle injury. Studies report improved collagen organization, enhanced fibroblast activity, and increased biomechanical strength, suggesting interaction with natural repair pathways in experimental systems.
Extensive preclinical research using rodent gut injury models, including NSAID-induced damage and ulcer formation, has examined BPC-157 as a cytoprotective compound. Laboratory findings suggest support for mucosal integrity, reduced lesion severity, and improved epithelial healing through angiogenesis and inflammation modulation.
BPC-157 has also been studied in connective tissue research involving muscles, ligaments, and bone systems. Experimental findings indicate stimulation of fibroblast proliferation, collagen production, and tissue remodeling responses following injury or stress.
BPC-157 is commonly supplied in 5MG and 10MG research vials to accommodate different experimental requirements. The 5MG option is suitable for lower-dose studies or titration experiments, while 10MG vials are preferred for larger-scale or extended research protocols.
BPC-157 should be stored in a dry, frozen environment protected from light and temperature fluctuations. During reconstitution and handling, aseptic laboratory procedures and proper personal protective equipment (PPE) should always be used.
BPC-157 is a research-grade peptide intended solely for in vitro and in vivo laboratory research. It is not approved by the FDA for therapeutic or human use. The World Anti-Doping Agency (WADA) classifies this compound under prohibited substances without authorized application. Results obtained from preclinical models cannot be directly applied to humans. Human research data remain limited, and potential risks such as immunogenicity may exist when sourced from unregulated materials. All information provided is for research and educational purposes only.
Reviews
There are no reviews yet.